$BCRX
BIOCRYST PHARMACEUTICALS INC

2017 Q1 Form 10-Q Financial Statement

#000117184317002784 Filed on May 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $9.437M $4.820M
YoY Change 95.79% -29.39%
Cost Of Revenue $290.0K
YoY Change
Gross Profit $9.140M $4.820M
YoY Change 89.63% -29.23%
Gross Profit Margin 96.85% 100.0%
Selling, General & Admin $3.058M $3.212M
YoY Change -4.79% -20.91%
% of Gross Profit 33.46% 66.64%
Research & Development $16.77M $20.58M
YoY Change -18.51% 20.2%
% of Gross Profit 183.48% 426.95%
Depreciation & Amortization $172.0K $47.00K
YoY Change 265.96% 4.44%
% of Gross Profit 1.88% 0.98%
Operating Expenses $19.83M $23.79M
YoY Change -16.66% 12.32%
Operating Profit -$10.69M -$19.05M
YoY Change -43.9% 32.0%
Interest Expense $2.100M $1.470M
YoY Change 42.86% 11.79%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.22M -$22.83M
YoY Change -37.71% 50.59%
Income Tax
% Of Pretax Income
Net Earnings -$14.22M -$22.83M
YoY Change -37.72% 50.57%
Net Earnings / Revenue -150.67% -473.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$189.2K -$310.2K
COMMON SHARES
Basic Shares Outstanding 73.96M
Diluted Shares Outstanding 75.17M 73.60M

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $98.68M $35.82M
YoY Change 175.52% -46.94%
Cash & Equivalents $75.16M $12.90M
Short-Term Investments $23.52M $22.91M
Other Short-Term Assets $4.600M $5.300M
YoY Change -13.21% -24.29%
Inventory $655.0K $1.949M
Prepaid Expenses
Receivables $9.564M $7.400M
Other Receivables $0.00 $0.00
Total Short-Term Assets $113.5M $50.43M
YoY Change 125.09% -38.05%
LONG-TERM ASSETS
Property, Plant & Equipment $9.753M $8.362M
YoY Change 16.63% 1094.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.800M $41.10M
YoY Change -90.75% 0.0%
Other Assets $2.271M $2.714M
YoY Change -16.32% -59.49%
Total Long-Term Assets $16.01M $52.46M
YoY Change -69.48% 8.16%
TOTAL ASSETS
Total Short-Term Assets $113.5M $50.43M
Total Long-Term Assets $16.01M $52.46M
Total Assets $129.5M $102.9M
YoY Change 25.89% -20.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.433M $7.691M
YoY Change -29.36% 45.11%
Accrued Expenses $11.34M $17.33M
YoY Change -34.59% -11.14%
Deferred Revenue
YoY Change
Short-Term Debt $28.40M $27.90M
YoY Change 1.79% -7.0%
Long-Term Debt Due $1.300M
YoY Change
Total Short-Term Liabilities $58.56M $63.07M
YoY Change -7.16% 1.89%
LONG-TERM LIABILITIES
Long-Term Debt $24.30M $2.500M
YoY Change 872.0%
Other Long-Term Liabilities $8.100M $9.500M
YoY Change -14.74% 163.89%
Total Long-Term Liabilities $32.40M $12.00M
YoY Change 170.0% 233.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.56M $63.07M
Total Long-Term Liabilities $32.40M $12.00M
Total Liabilities $91.00M $75.10M
YoY Change 21.17% 14.66%
SHAREHOLDERS EQUITY
Retained Earnings -$580.3M -$533.7M
YoY Change 8.72%
Common Stock $804.0K $737.0K
YoY Change 9.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.53M $27.80M
YoY Change
Total Liabilities & Shareholders Equity $129.5M $102.9M
YoY Change 25.89% -20.8%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$14.22M -$22.83M
YoY Change -37.72% 50.57%
Depreciation, Depletion And Amortization $172.0K $47.00K
YoY Change 265.96% 4.44%
Cash From Operating Activities -$8.527M -$18.84M
YoY Change -54.74% 405.09%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$3.260M
YoY Change -100.0% 471.93%
Acquisitions
YoY Change
Other Investing Activities $12.88M $5.970M
YoY Change 115.75% -276.63%
Cash From Investing Activities $14.13M $2.710M
YoY Change 421.51% -168.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $47.75M $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.70M 140.0K
YoY Change 34685.71% -90.67%
NET CHANGE
Cash From Operating Activities -8.527M -18.84M
Cash From Investing Activities 14.13M 2.710M
Cash From Financing Activities 48.70M 140.0K
Net Change In Cash 54.31M -15.99M
YoY Change -439.62% 158.74%
FREE CASH FLOW
Cash From Operating Activities -$8.527M -$18.84M
Capital Expenditures $0.00 -$3.260M
Free Cash Flow -$8.527M -$15.58M
YoY Change -45.27% 393.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
18000
CY2016Q1 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
233000
CY2017Q1 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
72000
CY2016Q4 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
77000
CY2017Q1 bcrx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
3803000
CY2016Q4 bcrx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
8926000
CY2017Q1 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
3116000
CY2016Q1 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
2930000
CY2017Q1 bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
3116000
CY2016Q1 bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
2930000
CY2017Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
220000
CY2017Q1 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
4482000
CY2017Q1 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
6402000
CY2017Q1 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
184000
CY2016Q4 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
199000
CY2017Q1 bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
-18000
CY2016Q1 bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
-19000
CY2017Q1 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
6313000
CY2017Q1 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive
324000
CY2017Q1 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
2344000
CY2017Q1 bcrx Increase Decrease In Financing Lease Obligations
IncreaseDecreaseInFinancingLeaseObligations
CY2016Q1 bcrx Increase Decrease In Financing Lease Obligations
IncreaseDecreaseInFinancingLeaseObligations
131000
CY2017Q1 bcrx Lease Financing Obligation Net Of Current
LeaseFinancingObligationNetOfCurrent
2704000
CY2016Q4 bcrx Lease Financing Obligation Net Of Current
LeaseFinancingObligationNetOfCurrent
2704000
CY2015Q1 bcrx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
150000000
CY2017Q1 bcrx Number Of Stockbased Compensation Plans
NumberOfStockbasedCompensationPlans
2
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5433000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4269000
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9564000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8768000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11335000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10836000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
618009000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
566913000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2462000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2645
CY2016Q4 us-gaap Assets
Assets
89847000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
113502000
CY2016Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
110000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2762000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1330000
CY2017Q1 us-gaap Assets
Assets
129513000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
66987000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
27327000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73782000
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80381000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73782000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
804000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
738000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14210000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22578000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
41472000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
27258000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41407000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
23524000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
32546000
CY2017Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
23524000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
32546000
CY2017Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
3803000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
8926000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75158000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22104000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28899000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12902000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
53054000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15997000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80381000
CY2017Q1 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-1543000
CY2016Q1 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-2753000
CY2017Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1301000
CY2016Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1228000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
155000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
20122000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
23868000
CY2017Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
82000
CY2016Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
85000
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
223000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
244000
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1869000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2022000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7888000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8184000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
172000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
47000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
19865000
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
337000
CY2017Q1 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-1543000
CY2016Q1 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-2753000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1642000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-541000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-449000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-480000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
284000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
546000
CY2017Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
796000
CY2016Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1141000
CY2017Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1252000
CY2016Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
353000
CY2017Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
109000
CY2016Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
439000
CY2017Q1 us-gaap Interest Expense
InterestExpense
2100000
CY2016Q1 us-gaap Interest Expense
InterestExpense
1470000
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2020000
CY2016Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1338000
CY2017Q1 us-gaap Interest Payable Current
InterestPayableCurrent
10291000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8990000
CY2017Q1 us-gaap Inventory Net
InventoryNet
655000
CY2016Q4 us-gaap Inventory Net
InventoryNet
500000
CY2017Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
655000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
500000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129513000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89847000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
58557000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54360000
CY2017Q1 us-gaap Line Of Credit
LineOfCredit
21611000
CY2016Q4 us-gaap Line Of Credit
LineOfCredit
22777000
CY2017Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1276000
CY2016Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
CY2017Q1 us-gaap Long Term Debt
LongTermDebt
23000000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
2300000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6900000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6900000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6900000
CY2017Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
CY2017Q1 us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
0
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
48700000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
138000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
12881000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2707000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8527000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18842000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-14219000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-22832000
CY2017Q1 us-gaap Notes Payable Current
NotesPayableCurrent
28353000
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
28243000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10685000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19048000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2271000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3813000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
254000
CY2017Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3000
CY2016Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3260000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1721000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1438000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47750000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47750000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
14136000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
6320000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
950000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9753000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9922000
CY2017Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
9564000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
8768000
CY2017Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0
CY2016Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16770000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20579000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2798000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1546000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-580280000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-566061000
CY2017Q1 us-gaap Revenues
Revenues
9437000
CY2016Q1 us-gaap Revenues
Revenues
4820000
CY2017Q1 us-gaap Royalty Expense
RoyaltyExpense
294000
CY2016Q1 us-gaap Royalty Expense
RoyaltyExpense
77000
CY2017Q1 us-gaap Royalty Revenue
RoyaltyRevenue
6321000
CY2016Q1 us-gaap Royalty Revenue
RoyaltyRevenue
1890000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
9437000
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
4820000
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3058000
CY2016Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3212000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2462000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2645000
CY2017Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.50
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6061000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
38530000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
1578000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</div></div></div>
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75167000
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73601000

Files In Submission

Name View Source Status
0001171843-17-002784-index-headers.html Edgar Link pending
0001171843-17-002784-index.html Edgar Link pending
0001171843-17-002784.txt Edgar Link pending
0001171843-17-002784-xbrl.zip Edgar Link pending
bcrx-20170331.xml Edgar Link completed
bcrx-20170331.xsd Edgar Link pending
bcrx-20170331_cal.xml Edgar Link unprocessable
bcrx-20170331_def.xml Edgar Link unprocessable
bcrx-20170331_lab.xml Edgar Link unprocessable
bcrx-20170331_pre.xml Edgar Link unprocessable
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10q_050817p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending